News

News 14.04.2023 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that further preclinical data supporting the company’s Radio DARPin Therapy Platform will be shared at the...

News 12.04.2023 BERLIN, Germany and ZURICH, Switzerland, April 12, 2023 / B3C newswire / -- ProBioGen and ImmunOs Therapeutics announce the extension of their partnership for further large-scale manufacturing of clinical material for IOS-1002, ImmunOs' lead program for the treatment of cancer. ProBioGen previously developed the cell line and the manufacturing process and provided the initial...

News 15.03.2023 Schlieren (Zurich), Switzerland, March 15, 2023 – Kuros Biosciences today announces continued robust progress with its results for full year 2022, increasing MagnetOs direct sales by 75% and completing enrollment of the randomized stage of the Phase 2 spine study for Fibrin-PTH, confirming its successful transition into a fully-fledged orthobiologics...

News 10.03.2023 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built proteins known as DARPin therapeutics, today announced its corporate highlights and audited financial results...

News 09.03.2023 Zurich-Schlieren, Switzerland, March 9, 2023. Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, today announced that new results evaluating Proclarix® in combination with imaging were published in BJU International[1]. The early detection of clinically significant prostate cancer decreases prostate cancer mortality. The use of multiparametric magnetic resonance imaging...